Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | CALML3 | P27482 | 6/20 | 0.53 |
| ▸ | HTR6 | P50406 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6191925 | 0.87 | F10 (0.55) | MAOAMAOBCALML3HTR6GRM2 | |
| SCHEMBL6192445 | 0.85 | MAOA (0.53) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL6213449 | 0.85 | MAOA (0.53) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL6210718 | 0.85 | MAOA (0.53) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL6210714 | 0.85 | MAOA (0.53) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL2184129 | 0.84 | MAOA (0.55) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL2184137 | 0.84 | MAOA (0.55) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL6195560 | 0.82 | MAOA (0.58) | MAOAMAOBCALML3F10 | |
| SCHEMBL5452213 | 0.82 | MAOA (0.50) | MAOAMAOBCALML3HTR6CYP2C9 | |
| SCHEMBL6195568 | 0.82 | MAOA (0.58) | MAOAMAOBCALML3F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1594494-A1 | OXAZOLIDINONE DERIVATIVES N-SUBSTITUTED BY A BICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20040224939-A1 | Antibacterial agents | CHUPAK LOUIS S (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004069244-A1 | OXAZOLIDINONE DERIVATIVES N-SUBSTITUTED BY A BICYCLIC RING, FOR USE AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224939-A1 | Antibacterial agents | MRPL21, RPN2, FBL | MAOA 236/4885MAOB 221/4885CALML3 4366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.